Vol. 21/No. 11 | OncologyLive

A New Generation of Drugs Targeting PD-1/PD-L1 Takes Shape in Oncology

June 08, 2020

OncologyLive

Over the past decade, immunotherapy has established itself as one of the pillars of cancer treatment, thanks in large part to the success of monoclonal antibodies that target the immune checkpoint protein PD-1 or its main ligand, PD-L1.

A New Generation of Drugs Targeting PD-1/PD-L1 Takes Shape in Oncology

June 08, 2020

Pathways

Over the past decade, immunotherapy has established itself as one of the pillars of cancer treatment, thanks in large part to the success of monoclonal antibodies that target the immune checkpoint protein PD-1 or its main ligand, PD-L1.

MIBC Trial Pairs 2 Immunotherapy Agents

June 05, 2020

Investigators are testing whether the addition of inhibitors targeting the PD-1 and IDO immune pathways to standard chemotherapy in the neoadjuvant setting will offer superior outcomes for patients with muscle-invasive bladder cancer.

Experts Provide Tips on Harnessing MRD to Guide ALL Therapy

June 04, 2020

During a recent OncLive Peer Exchange®, a panel of experts in adult and pediatric leukemia provided insight on how they use minimal or measurable residual disease (MRD) to guide treatment decisions, including transplantation and choice of therapy in patients who demonstrate MRD positivity after induction and first- and subsequent-line therapies.

Seeking a New Path for AL Amyloidosis

June 04, 2020

Immunoglobulin light chain amyloidosis is the most common form of systemic amyloidosis and is characterized by rapidly progressive organ failure and eventually patient demise, if not promptly recognized and treated.

Sacituzumab Govitecan Becomes First ADC Approved for TNBC

June 03, 2020

OncologyLive

Aditya Bardia, MD, MPH, discusses how the antibody-drug conjugate sacituzumab govitecan-hziy can address the unmet need in metastatic triple-negative breast cancer and the toxicities seen with the therapy.

Pandemic Poses a Crucial Moment for Science and the Public Trust

June 02, 2020

At this moment, we should consider what it will take for the scientific community as a collective entity to self-regulate far more forcefully so that the actions of a limited number of its members do not squander the well-deserved awakening of public trust in the entire scientific enterprise.